Oncolytics Biotech Inc. to Share New Pelareorep Insights
Oncolytics Biotech Inc. (NASDAQ: ONCY), a prominent player in the field of cancer immunotherapy, is set to make significant strides by presenting new data on pelareorep at the prestigious American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. This event will highlight the promising potential of pelareorep in tackling challenging gastrointestinal cancers, particularly focusing on pancreatic and anal cancers.
Discovering Pelareorep's Potential
Dr. Tom Heineman, Chief Medical Officer of Oncolytics Biotech, expressed excitement regarding the application of pelareorep across various cancer types. He noted, "Pelareorep plays a crucial role in enhancing the effectiveness of established treatments, such as chemotherapies and checkpoint inhibitors, including atezolizumab. By boosting the immune response, pelareorep aims to extend survival rates and delay the progression of these aggressive cancers." This enthusiasm reflects Oncolytics' commitment to harnessing innovative treatments to improve patient outcomes.
Key Presentations at the Symposium
During the ASCO symposium, two pivotal studies will be presented:
- Abstract Number: 6 - Title: Preliminary safety and tumor response results for the relapsed anal carcinoma cohort treated with pelareorep and atezolizumab. This will be showcased in the Poster Session C on January 25, 2025, at 7:00 AM PT.
- Abstract Number: 730 - Title: Safety run-in results for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep plus a modified regimen. This presentation will occur during Poster Session B on January 24, 2025, at 11:30 AM PT.
These abstracts will be publicly available on the symposium's website, providing further insight into the findings and implications of the research.
Understanding Pelareorep's Mechanism
Pelareorep is an innovative intravenous immunotherapeutic agent that has shown promise in earlier Phase 2 trials, particularly in metastatic breast and pancreatic cancer. Its mechanism revolves around inducing immune responses that help transform ‘cold’ tumors into ‘hot’ tumors, increasing their receptiveness to treatment. This strategy not only aims to target the cancer effectively but also enhances the overall efficacy of combination therapies.
Current Clinical Developments
Currently, Oncolytics is actively conducting trials that investigate pelareorep's synergistic effects with existing oncology treatments. The company is focused on developing combination strategies in solid tumors while preparing for registrational studies targeting breast and pancreatic cancers. The favorable Fast Track designation received from the FDA accelerates the path for pelareorep toward potential market approval.
Contacting Oncolytics Biotech Inc.
For inquiries and further information, potential investors and interested parties can reach out to:
Jon Patton
Director of IR & Communication
Investor Relations: Timothy McCarthy
LifeSci Advisors
Contact: +1-917-679-9282
Frequently Asked Questions
What is pelareorep and its significance?
Pelareorep is an intravenous immunotherapeutic agent developed by Oncolytics Biotech, showing potential to improve treatment effectiveness in hard-to-treat cancers.
When will the findings from the ASCO symposium be available?
Findings from the symposium will be published on January 21, 2025, at 5:00 PM ET on the ASCO website.
What existing treatments does pelareorep enhance?
Pelareorep has shown synergies with approved treatments, especially chemotherapies and checkpoint inhibitors like atezolizumab, making them more effective.
What are the expected benefits of pelareorep therapy?
Therapies involving pelareorep are anticipated to delay disease progression and improve survival in patients suffering from pancreatic and anal cancers.
How can I keep updated with Oncolytics Biotech Inc.?
Updates and news regarding Oncolytics Biotech can be followed through their official website and social media platforms such as LinkedIn and X.
